The IDEAYA Investor R&D Day Webcast agenda will be the following:

Agenda Topics

• Building Global Leader in Precision Medicine Oncology
  • IDEAYA Vision & Strategy
• Uveal Melanoma Roundtable
  • Treatment Paradigms in Neoadjuvant Uveal Melanoma
• New Paradigms to Address Tumor Heterogeneity and Drug Resistance
• Mechanistic Rationale Underpinning IDE161/Keytruda and IDE161/ADC Combination Opportunities
• IDEAYA and GSK Partnership
  • IDE275 / GSK959 (Phase 1) Werner Helicase Program Update by GSK
• Development Candidate Updates
  • IDE892 (PRMT5), IDE034 (B7H3/PTK7 Bispecific Topo ADC), and KAT6/7 Development Candidates

R&D Day Guest Speakers

• Carol Shields, M.D., Chief, Ocular Oncology Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University
• Amy Schefler, M.D., Partner at Retina Consultants of Texas, and Clinical Associate Professor at Weill Cornell Medical College, Houston Methodist Hospital and University of Texas Health Science Center at Houston
• Kornelia Polyak, M.D., Ph.D., Professor of Medicine at Dana-Farber Cancer Institute (DFCI), Harvard Medical School, a co-leader of the Cancer Cell Biology Program at the Dana-Farber Harvard Cancer Center, and a member of the National Academy of Sciences and the National Academy of Medicine
• Timothy Yap, MBBS, Ph.D., Professor, Department for Investigational Cancer Therapeutics and Department of Thoracic/Head and Neck Medical Oncology, Medical Director, Institute for Applied Cancer Science, Associate Director of Translational Research, Khalifa Institute for Personalized Cancer Therapy, M.D. Anderson Cancer Center
• Ramon Kemp, Ph.D., Vice President, Head, Oncology EDL, GSK